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Abstract
Background: Patients with fibromyalgia (FM) report widespread pain, fatigue, and other functional limitations. This
study aimed to provide an assessment of the burden of illness associated with FM in France and its association
with disease severity and core domains as defined by Outcome Measures in Rheumatology Clinical Trials
(OMERACT) for FM.
Methods: This cross-sectional, observational study recruited patients with a prior diagnosis of FM from 18
community-based physician offices in France. Patients completed questions about FM impact (Fibromyalgia-Impact
Questionnaire [FIQ]), core symptoms (defined by OMERACT), health-related quality of life (EQ-5D), current overall
health status (rated on a scale from 0 to 100), productivity, treatment satisfaction, and out-of-pocket expenses
related to FM. Site staff recorded patients’ treatment and health resource use based on medical record review.
Costs were extrapolated from 4-week patient-reported data and 3-month clinical case report form data and
calculated in 2008 Euros using a societal perspective. Tests of significance used the Kruskal-Wallis test or Fisher’s
Exact test where P < 0.05 was considered significant.
Results: Eighty-eight patients (mean 55.2 y; female:male 74:14) were recruited. The majority of patients (84.1%)
were prescribed medications for FM. Patients mainly described medications as a little/not at all effective (40.0%) or
somewhat effective (52.9%). Current Overall Health rating was 52.9 (± 17.8) and FIQ total score was 54.8 (± 17.3).
FIQ total score was used to define FM severity, and 17 patients scored 0- < 39 (mild FM), 33 patients 39- < 59
(moderate FM), and 38 scored 59-100 (severe FM). As FM severity level worsened, patients had poorer overall
health status and perceived their prescription medications to be less effective. Average cost/FM patient was higher
for severe (€10,087) vs. moderate (€6,633) or mild FM (€5,473); however, the difference was not significant.
Conclusions: In a sample of 88 patients with FM from France, we found that FM poses a substantial economic
and human burden on patients and society. FM severity level was significantly associated with patients’ health
status and core symptom domains.
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tology Clinical Trials (OMERACT)
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Fibromyalgia (FM) is a chronic disorder characterized by
persistent, widespread pain [1]. FM patients may also
report fatigue, sleep disturbance, anxiety, and depression
[2-4]. Although estimates vary, FM has been reported to
affect up to 6% of the general European population
[5-7]. However, one community study in France esti-
mated the point prevalence of FM to be lower at 1.4%,
which translates to ~680,000 patients [8].
Confirming a diagnosis of FM is often difficult because
there is no specific diagnostic test to clearly validate the
disorder. Indeed, FM is often diagnosed by ruling out
other conditions, such as rheumatoid arthritis, lupus, and
multiple sclerosis [9]. Various professional bodies have
issued guidelines to assist diagnosis of FM such as screen-
ing tools [10] or diagnostic criteria, such as those recently
issued by the American College of Rheumatology (ACR)
[11]. FM management guidelines published by the Ameri-
can Pain Society (APS) [12] and the European League
Against Rheumatism (EULAR) [13] reflect that generalized
pain does not adequately characterize FM and a broader
assessment of pain, function, and psychosocial aspects
may aid in FM management. Recognizing the need for a
core set of domains that more fully describe FM, the Out-
come Measures in Rheumatology Clinical Trials (OMER-
ACT) workgroup on FM was established to identify
domains that should be captured in clinical trials for FM
therapies [14]. These domains include pain, patient global
health, fatigue, health-related quality of life (HRQoL), mul-
tidimensional function, sleep, depression, physical func-
tion, tenderness, dyscognition, and anxiety.
Due in-part to the chronic nature of the disease, FM
patients are high consumers of healthcare services in
Europe [15-18]. The lack of a definitive diagnostic test
means that FM patients repeatedly present to physicians
prior to receiving a confirmed diagnosis. Furthermore,
once diagnosed patients often experience suboptimal
pain and symptom management which may lead to fre-
quent physician office visits [16]. A review of the litera-
ture shows that there are currently no studies that have
included a comprehensive assessment of the burden of
illness associated with FM in France. The objective of
this study was to better understand the impact of FM
on French patients by conducting an evaluation of their
clinical and comorbid profile, and FM’s impact on
HRQoL, symptom domains (such as pain, sleep, depres-
sion), productivity, and cost to society.
Methods
Study design
Sample population
This cross-sectional, observational study included FM
patients recruited from 18 community-based physician
offices (15 general practitioners and 3 rheumatologists)
in France. Since there are no definitive criteria for FM
diagnosis, patients were required to have a prior diagno-
sis of FM by a rheumatologist or pain specialist, to have
experienced widespread pain (above and below the waist
and on both sides of the body) for at least 3 months,
and to have experienced pain in the past 24 hours.
Patients also were required to have been in treatment at
the enrolling physician’s practice for at least 3 months.
All patients were older than 18 years of age and were
excluded if they had participated in an investigational
drug study within 30 days prior to the survey or had a
concomitant illness unrelated to FM that was likely to
confound the assessment of FM. The protocol was
approved by central and local accredited ethics commit-
tees. No medical interventions or invasive procedures
were required by the study protocol. All patients pro-
vided written informed consent.
Data collection procedures
Site study staff identified potential patients when they
presented for routine visits. Once patients provided
written informed consent, they were asked to complete
a self-administered patient questionnaire. Site staff com-
pleted a case report form (CRF) based on review of the
patient’s medical records and conducted an assessment
of FM using the Manual Tender Point Survey (MTPS)
exam [19]. Recorded data included patient’sc l i n i c a l
characteristics; patient specific pain associated with FM;
current and previous medications for FM; concomitant
medications prescribed for depression, anxiety, or
insomnia; and FM-related office visits, diagnostic tests,
and hospitalizations. Information collected via the
patient questionnaire and CRF was not associated with a
patient’s personal identification information but was
associated with a study-specific identifier assigned at
enrollment to allow linking of individual patients’ clini-
cal and survey data in the analysis.
Patient questionnaire
The patient questionnaire included five validated instru-
ments that assess the impact of FM on aspects of
HRQoL and symptoms (such as pain, sleep, anxiety, and
depression): the Fibromyalgia Impact Questionnaire
(FIQ) [20], the EuroQol (EQ-5D) [21], the Medical Out-
comes Study (MOS) Sleep Scale [22], the Brief Pain
Inventory-Short Form (BPI-sf) [23], and the Hospital
Anxiety and Depression Scale (HADS) [24]. Patients
were asked to rate their current overall health on a scale
from 0 to 100, where 0 represents ‘worst possible health’
and ‘100’ represents ‘perfect health’. Patients were also
asked to estimate what their overall health status would
be, on the same scale, if they had complete relief from
FM (pain-free overall health). In addition, study-specific
questions were developed to assess perceived treatment
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productivity and health resource use (HRU).
Patient perception of treatment effectiveness and
satisfaction
To assess perception of FM treatment effectiveness,
patients were asked questions relating to prescription
medications, non-prescription medications (e.g. over-
the-counter medications), and other treatments, includ-
ing physical treatments (physical therapy/massage, acu-
pressure/acupuncture, chiropracty), and herbs, vitamins,
or other supplements. Patients were specifically asked
how effective their prescription medications were for
relieving their FM symptoms over the past 4 weeks.
Response options for any question on effectiveness
were: extremely effective, very effective, somewhat effec-
tive, a little effective, and not at all effective. Similarly,
perceived satisfaction with treatment was assessed
through questions relating to prescription medications,
non-prescription medications, and other treatments
(listed above). Patients were specifically asked how satis-
fied or dissatisfied they were with the pain relief experi-
enced with their prescription medications over the past
4 weeks. Patients could respond to any question on
satisfaction with: extremely satisfied, somewhat satisfied,
neither satisfied nor dissatisfied, somewhat dissatisfied,
and extremely dissatisfied.
Health-related quality of life and core symptom domains
The EQ-5D utility score (derived from the health state
valuation score) assesses HRQoL across 5 domains, each
scored separately: mobility, self-care, performance of
usual activities, pain or discomfort, and anxiety or
depression [21]. A scoring formula developed by the
EuroQol Group is used to assign utility values for each
patient’s health valuation. Health state valuation scores
range from -0.594 to 1.00, where higher scores indicate
better health state [21].
The FIQ is a brief 10-item assessment measuring FM
patient status, progress, and outcomes in the area of
physical impairment, feeling good, work missed, doing
work, pain, fatigue/tired, rested, stiffness, anxiety, and
depression [20]. Each of the 10 subscales included in the
FIQ is scored from 0 to 10. The FIQ total score (range:
0-100) is the sum of the 10 FIQ subscale scores, with
higher scores indicating a greater impact of FM on the
patient. We utilized patients’ FIQ total scores to define
FM severity as follows: total scores of 0- < 39 consid-
ered mild; total scores of 39- < 59 considered moderate;
and total scores of 59-100 considered severe [25].
The BPI-sf includes an evaluation of pain intensity
and an evaluation of the interference of pain over the
past 24 hours on general activity, mood, walking, work,
relationships with others, sleep, and enjoyment of life
[23]. The intensity of pain is assessed with four items
(pain at its worst, at its least, on average over the past
24 hours, and currently) on an 11-point numeric rating
scale ranging from 0 to 10, where higher scores indicate
higher severity of pain. The BPI Pain Severity Index
score (range: 0-10) is the mean of worst, least, average,
and current pain, with previously established cut points
for chronic neuropathic pain of 0-3, 4-6, and 7-10 con-
sidered mild, moderate, and severe, respectively [26].
The MOS Sleep Scale includes 12 items that measure
seven key constructs of sleep: sleep disturbance, snoring,
awakening short of breath or with a headache, sleep ade-
quacy, somnolence, optimal sleep, and sleep quantity [22].
With the exception of optimal sleep (1 item; scored as 0
[not optimal] or 1 [optimal]), sleep quantity (1 item;
scored as 0-24 per hours of sleep where higher numbers
reflect more sleep), and sleep adequacy (2 items; combined
score of 0-100, where higher scores indicate greater sleep
adequacy), each of the other subscales and the additional
9-item Sleep Problems Index, were scored from 0 to 100
where higher scores represent worse sleep outcomes.
The HADS is designed to assess the presence and
severity of mood disorders and has been used exten-
sively in a variety of patient populations [24]. The
HADS includes 14 items, of which 7 assess anxiety
(HADS-A) and 7 assess depression (HADS-D); subscale
scores range from 0 to 21, with higher scores represent-
ing more symptoms and poorer emotional well-being.
Scores of 0-7 on either subscale are considered normal,
8-10 considered mild, 11-14 considered moderate, and
15-21 considered severe levels of anxiety and depression,
respectively.
Healthcare costs
Annual direct and indirect costs associated with FM
were calculated in 2008 Euros using a societal perspec-
tive. Costs included direct medical costs (diagnostic
tests, physician office visits, prescription medications,
hospitalizations, and patient out-of-pocket costs, e.g.
from prescription medications, non-prescription medica-
tions, and other treatments for FM), direct non-medical-
related costs (assistance with activities of daily living),
and indirect costs (days missed from work or on disabil-
ity due to FM).
Costing algorithms were developed to assign 2008 unit
costs to each unique type of resource utilized. Unit costs
assigned to office visits and office-based procedures were
based on current physician fee schedules (i.e. Classification
Commune des Actes Médicaux [CCAM]) [27]. Unit costs
assigned to hospitalizations were based on current hospital
case-rate payments (i.e. Programme de Médicalisation des
Systèmes d’Information [PMSI]) [28]. Medication costs
were based on private quotes for current drug price lists (i.
e. Thériaque) [29]. Unit costs assigned to days missed
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data. The average cost of FM, per patient, was summed
for the 3-month time horizon based on the data collected,
and the mean annual cost of FM, per patient, was calcu-
lated based on the 3-month data.
Statistical analyses
Summary statistics were calculated including mean, stan-
dard deviation (SD), median, and range for continuous
variables and frequency distributions for categorical vari-
ables. Data are given as mean (± SD) unless otherwise
indicated. To evaluate the impact of FM severity on
patient- and physician-reported outcomes, mean out-
comes and costs were compared across FM severity levels
(mild, moderate, and severe based on FIQ total scores
[25]) the Kruskal-Wallis test. Frequency outcomes were
compared across FM severity levels using Fisher’s exact
test. Statistical significance was evaluated at the 0.05
level, with no adjustments for multiple comparisons. The
data were held and analyzed by Covance Inc (Gaithers-
burg, MD, USA). All analyses were performed using SAS
version 9.1 (SAS Institute, Cary, NC, USA).
Results
Study sample
Eighty-eight patients from 18 community-based physi-
cian offices across France were enrolled. Patients were
55.2 (± 11.8) years and predominantly female (Table 1).
Patients had been diagnosed with FM for 3.2 (± 2.9)
years, on average, and half (52.3%) reported FM symp-
toms for 1-5 years (Table 2). The average number of
MTPS points was 13.0 (± 3.4). Patients had an average
of 3.4 comorbid conditions, with common (reported by
> 25% of patients) comorbidities being anxiety (76.1%),
sleep disturbance/insomnia (59.1%), and chronic fatigue
syndrome (52.3%).
Patients’ perception of treatment effectiveness and
satisfaction
All patients were actively seeking care for their FM.
Patients made 2.9 (± 1.9) office visits to the study site
over the past 3 months (Table 3). One-quarter (25.0%)
of patients also made visits to other physicians’ offices.
The more common physician specialties visited by
patients for their FM were rheumatologist (54.5%), gen-
eral practitioner (GP) (18.2%), neurologist (13.6%), and
surgeon (13.6%).
Most patients had received prescription medications
for their FM within the past 3 months (n = 74/88).
Among those receiving prescription medications for
FM, one or a combination of the following classes of
medications were prescribed: analgesics (59.1%), anti-
inflammatories (38.6%), antidepressants (28.4%), anxio-
lytics (28.4%), and muscle relaxants (26.1%) (Figure 1).
Assessment of patient’s perceived effectiveness of their
FM prescription medications found that no patient
Table 1 Demographic characteristics of study sample
FM Severity
Characteristic Total (n = 88) Mild
(n = 17)
Moderate (n = 33) Severe (n = 38) P-value
a
Age, years 0.303
Mean (SD) 55.2 (11.8) 51.3 (11.3) 56.1 (11.3) 56.2 (12.4)
Median (range) 57.0
(19.0-80.0)
55.0
(34-69)
57.0
(33-80)
57.5
(19-78)
Gender, n (%) 1.0
Male 14 (15.9) 3 (17.6) 5 (15.2) 6 (15.8)
Female 74 (84.1) 14 (82.4) 28 (84.8) 32 (84.2)
Employment status, n (%)
b 0.682
Employed, full-time 23 (26.1) 5 (31.3) 11 (33.3) 7 (21.9)
Employed, part-time 6 (6.8) 1 (6.3) 4 (12.1) 1 (3.1)
Disabled 8 (9.1) 1 (6.3) 3 (9.1) 4 (12.5)
Full-time homemaker 2 (2.3) 1 (6.3) 0 (0) 1 (3.1)
Unemployed 6 (6.8) 2 (12.5) 1 (3.0) 3 (9.4)
Retired 33 (37.5) 5 (31.3) 13 (39.4) 15 (46.9)
Other 2 (2.3) 1 (6.3) 1 (3.0) 0 (0)
Student 1 (1.1) 0 (0) 0 (0) 1 (3.1)
Patient Survey
aFisher’s exact test or Kruskal-Wallis test, as appropriate
bPercentages for each column might not add up to 100% due to missing data on given question.
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‘extremely effective’ (Figure 2). For patients who
responded as taking a prescription medication for FM
within the past 4 weeks (n = 70), the majority (52.9%)
reported medications as being ‘somewhat effective’ and
38.6% reported their prescription medications as being
‘a little effective’ (Figure 2). Assessment of patient’s
satisfaction with their FM prescription medications
found that no patient reported being extremely satis-
fied (Figure 3).
Impact of fm on health-related quality of life and core
symptom domains
With respect to overall functioning and well-being,
patients had an average EQ-5D health state score of
0.37 (± 0.33) (Table 4). The Current Overall Health rat-
ing was 52.9 (± 17.8), and patients estimated their Pain-
Free Overall Health 27.7 points higher (80.6) if they had
complete relief from FM-related pain (Table 4).
FIQ total score was 54.8 (± 17.3) (Table 4), with 17
(19.3%), 33 (37.5%), and 38 (43.2%) patients reporting
Table 2 Clinical characteristics of overall sample
FM Severity
a
Characteristic Total
(n = 88)
Mild
(n = 17)
Moderate
(n = 33)
Severe
(n = 38)
P-value
b
Duration of FM symptoms
c, n (%) 0.517
3-6 months 10 (11.4) 3 (17.6) 2 (6.1) 5 (13.2)
7-11 months 4 (4.5) 0 (0.0) 2 (6.1) 2 (5.3)
1-5 years 46 (52.3) 8 (47.1) 22 (66.7) 16 (42.1)
6-10 years 20 (22.7) 5 (29.4) 4 (12.1) 11 (28.9)
> 10 years 7 (8.0) 1 (5.9) 3 (9.1) 3 (7.9)
Time since diagnosis, years 0.983
Mean (SD) 3.2 (2.9) 3.2 (2.5) 3.1 (2.6) 3.4 (3.3)
Median 2 3 2 2
Number of positive MTPS points 0.165
Mean (SD) 13.0 (3.4) 14.4 (2.9) 12.6 (3.1) 12.7 (3.9)
Median 13 15 12 12
Comorbid conditions
d
Anxiety, n (%) 67 (76.1) 12 (70.6) 26 (78.8) 29 (76.3) 0.808
Sleep Disturbance/Insomnia, n (%) 52 (59.1) 10 (58.8) 22 (66.7) 20 (52.6) 0.477
Chronic Fatigue Syndrome, n (%) 46 (52.3) 13 (76.5) 17 (51.5) 16 (42.1) 0.055
Depression, n (%) 40 (45.5) 6 (35.3) 15 (45.5) 19 (50.0) 0.618
Headache/Migraine, n (%) 30 (34.1) 6 (35.3) 7 (21.2) 17 (44.7) 0.113
Restless Leg Syndrome, n (%) 22 (25.0) 8 (47.1) 8 (24.2) 6 (15.8) 0.043
Irritable Bowel Syndrome, n (%) 16 (18.2) 3 (17.6) 4 (12.1) 9 (23.7) 0.450
Raynaud’s Syndrome, n (%) 4 (4.5) 1 (5.9) 1 (3.0) 2 (5.3) 1.00
Other, n (%) 6 (6.8) 1 (5.9) 1 (3.0) 4 (10.5) 0.562
Number of comorbid conditions, n (%) 0.934
0 5 (5.7) 1 (5.9) 1 (3.0) 3 (7.9)
1 15 (17.0) 2 (11.8) 5 (15.2) 8 (21.1)
2 16 (18.2) 4 (23.5) 6 (18.2) 6 (15.8)
≥3 52 (59.1) 10 (58.8) 21 (63.6) 21 (55.3)
Number of comorbid conditions
e 0.637
Mean (SD) 3.4 (1.8) 3.8 (2.0) 3.2 (1.5) 3.5 (2.1)
Median (range) 3 (1-8) 4 (1-7) 3 (1-6) 3 (1-8)
Clinical case report form.
a Some data were not available, and therefore N-numbers for each group represents the maximum number of patients.
b Fisher’s exact test or Kruskal-Wallis test, as appropriate.
c Percentages for each column might not add up to 100% due to missing data.
d Categories are not mutually exclusive.
e Among patients reporting at least 1 comorbid condition
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severe scores (scores 59-100), respectively. FIQ domains
most affected (> 6.0) were feel good (7.1), fatigue/tired
(6.9), rested (6.8), stiffness (6.6), and pain (6.2) (Table 4).
BPI-sf Pain Severity Index was 4.9 (± 1.8) (Table 4),
with 54.5% of the patients reporting moderate pain
(scores 4-6) and 21.6% reporting severe pain (scores 7-
10). Pain Interference Index was 5.1 (± 1.9) (Table 4).
BPI domains most affected (score > 5) were normal
work (6.1), general activity (5.6), sleep (5.5), and enjoy-
ment of life (5.1) (Table 4).
Assessment of the sleep using the MOS found average
MOS Sleep Problems Index score of 52.8 (± 16.8), and
sleep quantity of 6.4 (± 1.7) hours (Table 4). The MOS
domain most affected was sleep adequacy (34.2 [± 24.1]),
where higher scores indicate greater sleep adequacy.
Assessment of anxiety using the HADS-A found
patients had average score of 10.4 (± 4.1) (Table 4).
Table 3 Number of physician visits for FM cohort, and stratified by FIQ-based FM severity
FM Severity
Characteristic Total (n = 88) Mild (n = 17) Moderate (n = 33) Severe (n = 38) P-value
a
Number of office visits over the past 3 months 0.319
Mean (SD) 2.9 (1.9) 3.1 (1.3) 2.5 (1.3) 3.3 (2.4)
Median 3 3 3 3
Other physician visits over the past 3 months
b, n (%) 0.379
Yes 22 (25.0) 2 (12.5) 10 (31.3) 10 (27.0)
No 63 (71.6) 14 (87.5) 22 (68.8) 27 (73.0)
Clinical case report form.
a Fisher’s exact or Kruskal-Wallis test, as appropriate.
b Percentages for each column might not add up to 100% due to missing data.
28.4%
28.4%
26.1%
18.2%
15.9%
13.6%
AntiͲdepressants
Anxiolytics
Musclerelaxants
AntiͲepileptics
Hypnotics
Missing
59.1%
38.6%
0% 20% 40% 60% 80% 100%
Otheranalgesics
AntiͲinflammatory
Subjects (%)
Figure 1 Percent of patients on medication, by class, over the past 3 months Clinical case report form. Patients may be prescribed
multiple medications so the categories are not mutually exclusive. The percent of patients receiving prescription medications for FM was 84.1%.
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anxiety (scores 0-7), 25.0% mild anxiety (scores 8-10),
and 35.2% moderate (scores 11-14) levels of anxiety.
Assessment of depression using the HADS-D found
average score of 7.9 (± 4.3) (Table 4), with 52.3%, 19.3%,
and 21.6% of the patients reporting normal (scores 0-7),
mild (scores 8-10), and moderate (scores 11-14) levels of
depression, respectively.
Impact of fm on productivity
Some level of disruption to their employment status due
to their FM was reported by almost half (44.3%) of all
patients, including having to reduce their work time
(18.2%), becoming disabled (13.6%), or becoming unem-
ployed or taking early retirement (12.5%). Among those
employed full- or part-time, all reported some degree of
reduced productivity while at work with an average of
Figure 2 Patient-reported perceived effectiveness of prescription medications for their FM. Patient Survey. Numbers may not add up to
100%. Fisher’s exact test performed across severity levels (P = 0.008)
Figure 3 Patient-reported satisfaction with prescription medications for their FM. Patient Survey, numbers may not add to 100%. Fisher’s
exact test performed across severity levels (P = 0.350)
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Scale Total
(n = 88)
Mild
(n = 17)
Moderate (n = 33) Severe (n = 38) P-value
a
EQ-5D
Health State valuation 0.37 (0.33) 0.65 (0.18) 0.44 (0.27) 0.18 (0.33) < 0.001
Overall Health Status Ratings
Current Overall Health 52.9 (17.8) 65.4 (14.2) 53.0 (11.9) 47.7 (20.9) 0.006
Pain-Free Overall Health 80.6 (19.2) 86.9 (12.8) 80.5 (22.6) 77.9 (17.6) 0.106
FIQ
Total Score 54.8 (17.3) 29.3 (8.8) 50.0 (5.5) 70.4 (8.5)
Physical Impairment 3.4 (2.1) 1.6 (1.9) 3.2 (2.0) 4.5 (1.7)
Feel Good 7.1 (2.8) 4.4 (2.9) 7.6 (2.5) 8.0 (2.3)
Work Missed 3.0 (3.5) 0.6 (1.9) 1.1 (2.1) 5.6 (3.3)
Do Work 6.0 (2.3) 3.2 (1.3) 5.4 (1.4) 7.6 (1.9)
Pain 6.2 (2.2) 3.2 (1.4) 5.9 (1.4) 7.9 (1.5)
Fatigue/Tired 6.9 (2.1) 4.7 (1.9) 6.7 (1.6) 8.3 (1.3)
Rested 6.8 (2.5) 4.3 (2.3) 6.5 (2.2) 8.1 (1.7)
Stiffness 6.6 (2.4) 4.0 (2.0) 6.5 (2.1) 8.0 (1.8)
Anxiety 5.3 (2.7) 2.4 (1.9) 4.7 (2.0) 7.1 (2.0)
Depression 4.3 (3.2) 1.2 (1.4) 3.2 (2.4) 6.6 (2.7)
BPI-sf
Pain Intensity: Worst 6.2 (2.0) 4.4 (1.9) 6.0 (1.4) 7.3 (1.8) < 0.001
Average pain 4.8 (1.9) 3.1 (1.7) 4.6 (1.3) 5.7 (1.8) < 0.001
Pain Severity Index 4.9 (1.8) 3.2 (1.4) 4.7 (1.2) 6.0 (1.7) < 0.001
Pain Interference Index 5.1 (1.9) 3.0 (1.1) 4.6 (1.2) 6.6 (1.6) < 0.001
General activity 5.6 (2.1) 3.7 (1.7) 5.3 (1.4) 6.8 (2.1) < 0.001
Mood 4.8 (2.6) 2.9 (2.3) 4.2 (2.1) 6.3 (2.3) < 0.001
Walking ability 4.6 (2.7) 2.2 (1.5) 4.2 (2.3) 6.0 (2.6) < 0.001
Normal work 6.1 (2.0) 3.7 (1.1) 5.6 (1.4) 7.6 (1.5) < 0.001
Relations with other people 4.0 (2.6) 1.9 (1.8) 3.2 (2.3) 5.7 (2.2) < 0.001
Sleep 5.5 (2.9) 3.8 (2.8) 4.5 (2.5) 7.1 (2.4) < 0.001
Enjoyment of life 5.1 (2.4) 2.9 (1.7) 4.7 (2.2) 6.5 (2.0) < 0.001
MOS
Sleep Problems Index 52.8 (16.8) 45.9 (20.5) 48.6 (14.9) 59.5 (14.4) 0.008
Sleep disturbance 53.8 (25.1) 47.6 (27.8) 49.8 (24.6) 60.1 (23.6) 0.106
Sleep adequacy 34.2 (24.1) 42.4 (24.4) 34.6 (22.9) 30.3 (24.7) 0.201
Sleep somnolence 43.3 (22.6) 38.8 (26.7) 36.0 (18.9) 51.6 (21.4) 0.006
Snoring 43.9 (31.2) 38.7 (29.7) 36.4 (28.0) 53.5 (32.9) 0.074
Sleep SOB or headache 35.2 (26.9) 25.0 (33.9) 27.3 (23.4) 46.3 (22.8) 0.001
Sleep quantity (hours) 6.4 (1.7) 6.5 (1.6) 6.8 (1.4) 6.0 (1.9) 0.092
HADS
Anxiety 10.4 (4.1) 8.0 (4.1) 9.9 (2.9) 11.9 (4.4) 0.002
Depression 7.9 (4.3) 4.7 (3.0) 6.6 (3.3) 10.5 (4.0) < 0.001
Patient Survey
aKruskal-Wallis test.
SOB, shortness of breath
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Page 8 of 132.7 days of work missed in the previous 4 weeks (Table
5).
Impact of fm on healthcare costs
Total annual costs per patient for treating FM in France
was €7,900 (€14,868), comprising direct costs of €910,
and indirect costs of €6,990 (Table 6). Lost productivity
accounted for the majority of costs (~88.5% total costs
[direct+indirect]) associated with FM. The major cost
drivers for the direct medical costs were payer costs for
physician office visits (€259/€808 [32.1%]) and payer
costs for prescription medications (€245/€808 [30.3%]).
Patient direct medical costs (€186) accounted for 23.0%
of direct medical costs (Table 6).
Impact of FM severity
Baseline characteristics were similar across FM severity
cohorts, including age, gender, and employment status
(Table 1). Almost half (15/32 [46.9%]) of the severe FM
patients were retired and a further 21.9% were disabled
or unemployed. Time since diagnosis of FM was similar
across patients in different severity cohorts (~3 years)
(Table 2). None of the clinical characteristics differed
significantly across FM severity levels (Table 2) except
for the proportion of patients with restless leg syndrome
(RLS), which was highest in patients with mild FM
(47.1%) (P = 0.043). Interestingly, more than 70% of
patients in each FM severity cohort reported anxiety,
and at least 50% in each severity cohort reported sleep
disturbance/insomnia.
With regard to healthcare visits, there was no associa-
tion between FM severity and number of office visits
within the past 3 months (Table 3) An association was
found between FM severity level and the EQ-5D health
state valuation score (mild: 0.65, moderate: 0.44, severe:
0.18; P < 0.001), where poorer overall health status was
associated with more severity (Table 4) Additionally,
there was an association between FM severity level and
current overall health scores, where current overall
health score decreased from 65.4 to 53.0 to 47.7 for
mild to moderate to severe FM, respectively (P =0 . 0 0 6 )
(Table 4). As might be expected, an association was also
found between FM severity level and BPI-sf Pain Sever-
ity Index scores from 3.2 for patients with mild FM, 4.7
with moderate FM, and 6.0 with severe FM (P < 0.001)
(Table 4). Pain interference index also differed across
FM severity level, from 3.0 for patients with mild FM to
4.6 for those with moderate FM, and to 6.6 for patients
with severe FM (P < 0.001).
An association between FM severity level and certain
sleep outcomes was found (Table 4). For example, MOS
Sleep Problems Index increased as FM FIQ severity
increased, from 45.9 for patients with mild FM, to 48.6
for patients with moderate FM, and 59.5 for severe FM
(P = 0.008). Using the HADS-A patients reported
increasing anxiety as FM severity worsened from mild
(8.0) to moderate (9.9) to severe (11.9) (P = 0.002). The
HADS-D scores showed a similar trend indicating
increasing depression as the FM severity level worsened
(4.7, 6.6, 10.5, respectively; P < 0.001) (Table 4). Com-
parisons across FM severity level for the FIQ are not
made because FM severity level was developed from the
FIQ total score.
Nearly three-quarters (74.2%) of patients in the severe
FM cohort reported FM-related disruptions in employ-
ment status. Although not significant, the average num-
ber of days missed from work due to FM during the
past 4 weeks was 0.5 days for mild, 1.2 days for
Table 5 Impact of FM on productivity among patients employed for pay
FM Severity
Characteristic Total
(n = 29)
Mild
(n = 6)
Moderate (n = 15) Severe
(n = 8)
P-value
a
Days missed from work during the past 4 weeks
b 0.309
n 27 6 13 8
Mean (SD) 2.7 (6.0) 0.5 (1.2) 1.2 (2.8) 6.9 (9.6)
Median (range) 0 (0-20) 0 (0-3) 0 (0-8) 0 (0-20)
Reduced productivity at work during the past 4 weeks
b, n (%) 0.281
All of the time 4 (13.8) 0 (0.0) 2 (13.3) 2 (25.0)
Most of the time 4 (13.8) 0 (0.0) 3 (20.0) 1 (12.5)
A good bit of the time 9 (31.0) 1 (16.7) 4 (26.7) 4 (50.0)
Some of the time 11 (37.9) 4 (66.7) 6 (40.0) 1 (12.5)
A little of the time 1 (3.4) 1 (16.7) 0 (0.0) 0 (0.0)
None of the time 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Patient Survey.
aFisher’s exact test or Kruskal-Wallis test, as appropriate.
bAmong patients who are employed (full-time or part-time).
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Page 9 of 13moderate, and 6.9 days for severe FM (P = 0.309) (Table
5). There also was no significant relationship between
FM severity level and at-work productivity over the past
4 weeks.
As FM severity level worsened, patients perceived
their prescription medications to be less effective (Figure
2) (P =0 . 0 0 8f o ra s s o c i a t i o na c ross cohorts). Patients
also generally became less satisfied with their prescrip-
tion medication as severity level worsened (Figure 3),
although the association was non-significant.
Average annual total cost (direct and indirect) per FM
patient was higher for patients with severe FM (€10,087)
compared to those with moderate (€6,633) or mild FM
(€5,473); however, the difference was not significant
(Table 6). As observed overall, lost at-work productivity
was the main driver of total costs within each severity
level.
Discussion
This is the first study to assess core FM symptom
dimensions identified by OMERACT, in a group of 88
patients with FM from France. We examined FM bur-
den of illness by investigating patients’ tender points,
HRQoL, general health, pain, sleep/fatigue, depression,
anxiety, physical function, productivity losses for FM
patients, medication use, treatment satisfaction, as well
as the costs to society. Consistent with other studies
[4,30-32], our study demonstrated that patients have
substantial burden due to FM, and FM is associated
with direct and indirect costs.
The results of this study show a significant burden of
illness associated with FM. FM severity was associated
with certain sleep problems, anxiety, and depression.
Patients reported poor HRQoL, overall and in negative
health impact in relation to measures of pain, function,
sleep, anxiety, and depression. Just over half (55%) of
patients had moderate pain based on the BPI-sf Pain
Severity Index, and 22% severe pain, supporting that
moderate-to-severe chronic pain is a dominant feature
for patients with FM.
Although the generalizability of our observations from
these FM patients to the wider FM population in France
is ultimately unknown, our results are consistent with
other larger studies that have examined the impact of
FM. For example, a Dutch study involving a sample of
3664 patients and examining the impact of musculoske-
letal diseases on HRQoL, reported that patients with
FM (with or without other musculoskeletal diseases)
scored lower on all subscales of the Short Form-36 (SF-
36) and EQ-5D health status measures than study
patients with other musculoskeletal diseases [33]. The
domains most affected were vitality, role-physical, and
bodily pain for the SF-36; and usual activities and pain/
discomfort for the EQ-5D. In a study of chronic wide-
spread pain among patients with and without FM in
Sweden, the FM group scored significantly lower than
Table 6 Annual costs (2008 Euros) per FM patient, and by FM severity
Resource Utilization Cost Total
(n = 88)
Mild
(n = 17)
Moderate
(n = 33)
Severe
(n = 38)
Mean (SD) Median Mean (SD) Median Mean (SD) Median Mean (SD) Median P-
value
a
Direct Medical Costs to Payer
b
Physician Visits 259 (163) 264 271 (118) 264 219 (112) 264 288 (208) 264
Diagnostic Tests 14 (38) 0 26 (61) 0 7 (20) 0 13 (37) 0
Prescription Medications 245 (345) 107 153 (207) 43 213 (312) 102 314 (409) 144
Hospitalizations 104 (972) 0 0 (0) 0 276 (1,587) 0 0 (0) 0
Direct Medical Costs to Patient
c 186 (425) 0 113 (256) 0 233 (448) 0 179 (467) 0
Total Direct Medical Costs to Society 808 (1,215) 540 564 (440) 528 949 (1,842) 504 794 (636) 595 0.434
Direct Non-Medical Cost to Patient
c
Professional services for ADL 103 (501) 0 93 (274) 0 108 (428) 0 103 (633) 0
Total Indirect Costs to Society
c
Lost productivity 6,990
(14,561)
0 4,816
(12,433)
0 5,576
(12,736)
0 9,190 (16,808) 0
Total Direct and Indirect Costs to
Society
7,900
(14,868)
616 5,473
(12,852)
610 6,633
(13,498)
528 10,087
(16,785)
890 0.185
Extrapolated from 4-week patient-reported data and 3-month clinical case report form data
aKruskal-Wallis test.
bBased on unit cost and data reported in Clinical case report form.
cBased on patient-reported data from study.
ADL: activities of daily living
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Page 10 of 13the non-FM group on general HRQoL measures and
specific measures for activities of daily living, depression,
anxiety, and pain [34]. Collectively with our study, data
highlight the high societal and patient burden that FM
inflicts across Europe [35].
Patients in our study reported a significant impact of
FM on sleep, with the most affected areas on the MOS
Sleep Scale being sleep adequacy and sleep disturbance.
These observations are consistent with other larger stu-
dies of European patients with FM, and FM patients
from other countries [3,36] For example, in a study of
600 health maintenance organization (HMO) members
with FM [3], patients demonstrated poor sleep quality
as measured by the Pittsburgh Sleep Quality Index
(PSQI) where scores of ≥5 indicates poor sleep. More
specifically, Bigatti et al. reported patients had PSQI
score of 11.22 (± 3.96) at baseline, with only 4% of
patients scoring < 5 [3].
FM had a negative impact on work productivity in the
present study, with 44% of patients reporting some dis-
ruption in productivity, and the overall employed sam-
ple reporting an average of 35 days of missed work per
year per patient. Thirty-five days of missed work due to
FM accounts for approximately 13% of all working days
in a calendar year. Other studies have likewise high-
lighted the higher number of work days missed for
employed patients with FM vs. the general population,
in Europe and the United States. For example, in a simi-
lar small study of patients with FM, chronic low back
pain, and ankylosing spondylitis, Boonen et al. (2005)
found that 63% of FM patients with a paid job reported
an episode of sick leave, with mean length of sick leave
was 34 days per working-patient-year [15]. In a larger
study of administrative claims database including 31
large self-insured companies in the United States, White
et al. (2005) reported that FM patients missed signifi-
cantly more days of work in the past year compared
with non-FM patients (29.8 vs. 10.4 days; P < 0.001) [4].
Similarly, a study of 1081 patients with FM from Spain
reported 20.9 sick days per year, significantly more than
the reference group of subjects without FM syndrome (8
days) [32].
Patients reported an average of one physician office
visit per month in the present study. Physicians reported
that 84% of patients were taking a prescription medica-
tion related to their FM symptoms, with the majority of
patients taking other analgesics, primarily opioids, and
non-steroidal anti-inflammatory drugs. Furthermore,
patients did not perceive their prescription medications
as completely effective and expressed some dissatisfac-
tion with current pharmacological treatments. Our find-
ings suggest that there is room for improvement in the
current management and use of prescription medica-
tions for FM in France. These observations are relatively
consistent with other larger studies of European popula-
tions of FM patients. For example, a study of 299
patients with FM from France and Germany reported
that their FM treatment regimens were not the most
advantageous [18]. Other European studies have also
documented frequent physician office services among
patients with FM. In a UK study using a large electronic
medical records database containing data on GP visits,
Hughes et al. (2006) reported that, among 2,260 UK
patients newly diagnosed with FM, there were 25 office
visits, and 11 prescriptions per patient in the year prior
to diagnosis, and levels of HRU generally increased fol-
lowing diagnosis [16]. Using a large electronic database
recording GP encounters in Germany, Berger et al.
(2008) also demonstrated significant HRU for FM
patients. Among 4,983 FM patients, 67% were on at
least one pain-related medication and 74% had four or
more GP office visits over 1 year. Additionally, FM
patients averaged approximately three-times as many
outpatient office visits (19.6 vs. 5.2; P <0 . 0 0 1 )t h a n
patients without FM [17]. Similarly, a claims analysis
from Spain documented an average of 13.5 GP office
visits per year and the use of an annual average of 3.7
medications for 1081 FM patients [32]. Taken with the
data presented in the current study, despite diagnosis
and treatment, FM patients display considerable HRU
across Europe, indicating an unmet need for FM
patients in these studies.
Higher HRU rates resulted in higher total direct medi-
cal costs on a per-patient basis. The major drivers of
direct medical costs to the payer were physician office
visits and prescription medications. The largest contri-
bution to FM costs in our study was related to lost pro-
ductivity due to absenteeism and disability, accounting
for approximately 88% of total costs. These results are
supported by the published literature. Previous studies
have demonstrated that employee disability and medical
comorbidity associated with FM greatly increase the
economic burden of the disease. White et al. (2008)
reported that indirect costs, including actual employer
payments for extended absence from work due to dis-
ability and imputed medically-related work-loss days
and costs, accounted for approximately one-third of the
total study costs, highlighting the significant burden
imposed by FM to employers [4]. Robinson et al. (2003)
also found that a substantial portion of total cost for
FM was due to work disability; the prevalence of disabil-
ity was twice as high among employees with FM when
compared with the overall employee population [37].
The present study is the first to assess the impact of
FM severity on key multiple FM dimensions. Eighty-one
percent of the sample reported moderate (38%) or
severe FM (43%) based on patients’ FIQ total scores and
the results of the study also show that, as FM severity
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Page 11 of 13increased, facets of patients’ HRQoL, pain, elements of
sleep, anxiety, and depression worsened significantly. In
addition, there was a non-significant trend for patients’
productivity and the total direct and indirect costs to
society to increase as FM severity worsened.
This study had several limitations. Firstly, only practices
that volunteered to participate were included in the
study. It is possible that these sites may differ in
unknown ways from others that routinely provide FM or
general patient care. Additionally, these practices were
predominantly GPs, and it is possible that FM patients
presenting to GPs are not generalizable to the FM patient
population in France as a whole. However, we note that
GPs are the most accessible venue for FM patients to
seek care, and a large proportion of patients were concur-
rently seeking care for their FM from other specialists.
Data came from patients who were actively seeking care;
the clinical/sociodemographic characteristics of FM
patients who were not seeking care are not known, and
our findings may not be generalizable to the wider FM
patient population. It is possible that differences were not
significant because the low number of patients in each
severity cohort is underpowered to detect differences.
Therefore these outcomes warrant further investigation
in studies with larger sample sizes. Although each scale
used in the present study has been independently vali-
dated to assess given symptoms in different patient popu-
lations, they have not all been validated in FM patients
specifically. However, the scales picked are widely used in
FM clinical trials to assess subjective outcomes, and some
scales are recommended to healthcare providers for
assessment of symptoms. Our costing algorithm made
several assumptions that may have underestimated medi-
cation costs, including costing based on generic medica-
tions, determining costs using the largest package sizes
available, and assuming lowest average dose where infor-
mation from the CRF was incomplete. A less conservative
costing methodology might have led to higher estimated
costs associated with medications. While we captured
out-of-pocket costs incurred by patients for non-prescrip-
tion medications and services by allied healthcare profes-
sionals beyond the GP/hospital environment, these types
of services and costs often recommended to FM patients,
such as physiotherapists, exercise specialists, or psy-
chotherapists, may have been underreported and
increased the cost burden to patients or society as a
result. Finally, the study was cross-sectional; therefore,
while we can examine the association between FM and
outcome measures, directionality cannot be established.
Despite these limitations, gi v e nt h el a c ko fi n f o r m a t i o n
on the burden of FM in patients from France; our study
provides important insights into the impact of FM in this
sample of patients with FM from France.
Conclusion
This study represents one of the first attempts to char-
acterize the full patient experience of disease, function,
HRQoL, and costs of patients with FM from France.
Although the majority of patients were receiving medi-
cal attention and prescription medications for FM,
patients still reported high levels of pain, anxiety,
depression, sleep disturbance, diminished HRQoL, and
substantial loss of productivity. Additionally, patients
reported that prescription medications for their FM
were not optimal in terms of perceived effectiveness and
satisfaction. As FM severity increased, patients’ health
status and other key symptom domains worsened.
Finally, the total direct and indirect costs to society
increased as FM severity increased. These results high-
light the significant disease burden as well as limitations
of treatment options available.
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